Related Experiment Video
Updated: Jul 9, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Overview of Parkinson's disease
1Division of Movement Disorders, Department of Neurology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA. mlew@surgery.usc.edu
Pharmacotherapy
|November 29, 2007
Summary
Parkinson's disease is a progressive neurodegenerative disorder affecting movement due to dopamine neuron loss. While incurable, treatments manage motor and non-motor symptoms, with research exploring disease modification.
Area of Science:
- Neurology
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) is a prevalent, progressive neurodegenerative disorder.
- It significantly impacts patient quality of life and functional independence.
- The underlying cause remains unknown, but pathological hallmarks include dopaminergic neuron loss in the substantia nigra.
Purpose of the Study:
- To provide a foundational overview of Parkinson's disease.
- To contextualize pharmacotherapy strategies for Parkinson's disease management.
- To highlight current research directions in PD treatment.
Main Methods:
- Literature review and synthesis of existing knowledge on Parkinson's disease.
- Clinical manifestation and diagnostic criteria overview.
- Summary of current and emerging pharmacologic interventions.
Main Results:
- Characteristic motor symptoms include tremor, rigidity, and bradykinesia, often responsive to levodopa.
- Advanced stages present with postural instability and gait disturbances.
- Current treatments focus on symptom management, not disease modification.
Conclusions:
- Parkinson's disease management involves addressing both motor and non-motor symptoms.
- Pharmacotherapy is crucial for alleviating disability and improving quality of life.
- Ongoing research aims to identify disease-modifying therapies for Parkinson's disease.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.